User fee audit
This article was originally published in The Gray Sheet
Executive Summary
FDA holds conference call with Health Industry Manufacturers Association reps Jan. 24 to discuss results of a HIMA-commissioned Price Waterhouse audit of the agency's user fee budget model. While the report affirms the validity of the agency's basic model, FDAers say, it also questions some of FDA's assumptions used in determining revenues required by the program. As a result, Price Waterhouse reportedly arrived at lower user fee program cost estimates than FDA's current figures
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.